Literature DB >> 15968091

Immunophenotyping of plasma cells in multiple myeloma.

Gema Mateo Manzanera1, Jesús F San Miguel Izquierdo, Alberto Orfao de Matos.   

Abstract

Multiparametric immunophenotyping of multiple myeloma (MM) and other plasma cell (PC) dyscrasias represents an attractive approach not only for research purposes but also in clinical practice. Based on well-established antigenic patterns, discrimination between myelomatous and normal PCs can be easily achieved in various types of samples, and this can be particularly valuable for the differential diagnosis between MGUS and MM and for monitoring residual disease in the latter. In addition, immunophenotyping may be an alternative and more reproducible method than morphology for evaluating PC infiltration, as well as for specifically analyzing DNA content and the cell-cycle distribution of different subsets of PCs. Despite the widespread use, standardization of methods and protocols still remains a challenge. In this chapter, we describe in detail the protocols and precise instructions for specimen collection, sample preparation, together with the methods for staining PCs and flow cytometry, data acquisition, and data analysis, including the more recent developments in the field. We highlight the most frequent limitations, and provide troubleshooting and practical recommendations that could help to solve them. The goal of this chapter is to emphasize the relevance of methodological issues in order to obtain reproducible and high-quality results regarding the phenotypic analysis of PCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968091     DOI: 10.1385/1-59259-916-8:5

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  9 in total

1.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

Review 2.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

Review 3.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

Review 4.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 5.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

6.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

7.  Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jose J Pérez; Gema Mateo; Maria Angeles Montalbán; Maria Victoria Mateos; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

8.  Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients.

Authors:  Fatemeh Zamani; Mansoureh Shokripour; Maral Mokhtari
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-07-01

9.  Detection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.

Authors:  Suzane Dal Bó; Annelise Pezzi; Bruna Amorin; Vanessa Valim; Rosane Isabel Bittencourt; Lucia Silla
Journal:  ISRN Hematol       Date:  2013-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.